WallStSmart

Cosmos Health Inc. (COSM)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 77705% more annual revenue ($57.36B vs $73.73M). NVS leads profitability with a 17.5% profit margin vs -33.1%. NVS earns a higher WallStSmart Score of 48/100 (D+).

COSM

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

NVSSignificantly Overvalued (-67.6%)

Margin of Safety

-67.6%

Fair Value

$95.76

Current Price

$160.50

$64.74 premium

UndervaluedFair: $95.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
28.8%8/10

Revenue surging 28.8% year-over-year

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$302.86B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.0%10/10

Strong operational efficiency at 34.0%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

COSM4 concerns · Avg: 3.3/10
Price/BookValuation
9.6x4/10

Trading at 9.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Revenue Growth. Revenue growth of 28.8% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.

Bear Case : COSM

The primary concerns for COSM are Price/Book, EPS Growth, Market Cap.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

COSM profiles as a growth stock while NVS is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.44 — expect wider price swings.

COSM is growing revenue faster at 28.8% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 36/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?